Y. Sugiyama

发表

Nonpalpable testicular pure seminoma with elevated serum alpha-fetoprotein presenting with retroperitoneal metastasis: a case report

K. Tozawa, T. Naiki, T. Nagai, 2016, Journal of Medical Case Reports.

Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report

T. Naiki, T. Yasui, Yuko Yamamoto, 2018, Journal of Pharmaceutical Health Care and Sciences.

Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis

H. Miyake, T. Naiki, T. Yasui, 2021, International Journal of Clinical Oncology.

A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy

A. Naiki‐Ito, T. Naiki, T. Yasui, 2022, IJU case reports.

First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma

T. Naiki, S. Nozaki, T. Nagai, 2021, Oncology.

Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis

T. Naiki, T. Nagai, T. Etani, 2020, Oncology.

Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy

T. Naiki, S. Nozaki, T. Nagai, 2019, Asian Pacific journal of cancer prevention : APJCP.

Intravenous Administration of Apomorphine Does NOT Induce Long QT Syndrome: Experimental Evidence from In Vivo Canine Models

H. Yamazaki, N. Murayama, A. Sugiyama, 2015, Basic & clinical pharmacology & toxicology.

Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan

T. Naiki, T. Akechi, K. Kimura, 2018, Japanese journal of clinical oncology.

Effectiveness of continuous monitoring by activity tracker of patients undergoing chemotherapy for urothelial carcinoma.

Keitaro Iida, T. Naiki, S. Nozaki, 2020, Cancer treatment and research communications.

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade

Keitaro Iida, T. Naiki, T. Nagai, 2017, Prostate international.

Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma

Keitaro Iida, T. Naiki, S. Nozaki, 2021, In Vivo.

Prognostic significance of hyponatremia induced by systemic chemotherapy in a hospital-based propensity score-matched analysis

Keitaro Iida, T. Naiki, S. Nozaki, 2019, International Journal of Clinical Oncology.

Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis

A. Naiki‐Ito, Keitaro Iida, T. Naiki, 2021, International Journal of Clinical Oncology.

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis

T. Naiki, T. Nagai, T. Etani, 2018, Cancer management and research.

Syndrome of Inappropriate Secretion of Antidiuretic Hormone Caused by Carboplatin After Switching from Cisplatin in a Metastatic Urethral Cancer Patient

T. Naiki, T. Yasui, K. Kimura, 2017, Urology case reports.

Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma

Yoko Furukawa-Hibi, T. Naiki, T. Etani, 2023, International journal of urology : official journal of the Japanese Urological Association.

Usage and Distribution for Commercial Purposes Requires Written Permission. a Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-line Chemotherapy with Discussion and Literature Review

A. Naiki‐Ito, Keitaro Iida, T. Naiki, 2022 .

A Retrospective Study on the Effectiveness of Switching to Oral Methadone for Relieving Severe Cancer-Related Neuropathic Pain and Limiting Adjuvant Analgesic Use in Japan.

M. Ohsawa, T. Akechi, H. Takeyama, 2016, Journal of palliative medicine.

Survival Outcome after Reduced-Port Laparoscopic Radical Cystectomy for Bladder Cancer: Long-Term Follow-Up Analysis

A. Naiki‐Ito, T. Naiki, T. Nagai, 2022, Oncology.

GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma

T. Naiki, S. Nozaki, T. Nagai, 2023, Oncology.

Pure Lymphoepithelioma-Like Carcinoma Originating from the Urinary Bladder

Keitaro Iida, T. Naiki, T. Nagai, 2016, Case Reports in Oncology.

Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma

T. Naiki, T. Etani, N. Kawai, 2023, International journal of urology : official journal of the Japanese Urological Association.

Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma

Keitaro Iida, T. Naiki, S. Nozaki, 2020, Oncology.

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma

T. Naiki, T. Nagai, T. Etani, 2017, Journal of rural medicine : JRM.

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy

A. Naiki‐Ito, T. Naiki, T. Nagai, 2017, Case Reports in Oncology.

Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma

T. Naiki, T. Etani, S. Hamamoto, 2024, Journal of clinical medicine.

Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study

T. Naiki, H. Komatsu, T. Shimura, 2023, Cancer medicine.

Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma

T. Naiki, T. Etani, R. Ando, 2024, Scientific reports.

C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study

A. Naiki‐Ito, T. Naiki, T. Etani, 2024, Cancers.

Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.

T. Shimura, S. Hamamoto, R. Ogawa, 2024, Asia-Pacific journal of clinical oncology.